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The race to uncover new biological drug targets has led to an emerging field of 
research on the thermodynamic properties that stabilize transmembrane proteins as well
as the role of these stabilizing factors in shaping the evolutionary landscape of drug target
populations. When proteins are inserted into the plasma membrane, they fold into three-
dimensional secondary protein structures called alpha helices. The electrical interactions 
within the alpha helix causes the protein to form a macrodipole. As a result of this 
phenomenon, the energetic stabilities of TM proteins may either be disrupted or enhanced
due to the interactions between the surrounding membrane potential and the charged
dipole termini of the folded helix. Currently, the relative contributions of compensatory
factors to TM protein stability and their population distributions are poorly understood. In
this study, two categories of bitopic proteins and the hydrophobic energies of their TM 
domains were investigated. We hypothesized that Type I TM proteins exhibit lower
hydrophobic free energies as a compensatory response to the decreased electrical
stabilities of Type I proteins that have incurred an energetic penalty due to the spatial
orientations. A Z test showed that Type I proteins exhibit significantly lower hydrophobic 
free energies than Type II proteins (p = = 0.05). A Z test of Shannon entropies
of both protein types revealed that Type 1 proteins exhibit significantly lower Shannon 
entropies than those of Type 2 (p = 0.000, = 0.05). Linear regression analysis showed a
weak correlation between Type I Shannon entropies and Type I hydrophobic energies (R2
= 0.221) and Type II Shannon entropies and Type II hydrophobic energies (R2 = 0.232),
 
suggesting that Shannon entropies are not a direct function of hydrophobic free energies 
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Natural selection is the primary mechanism that is hypothesized to govern 
evolutionary processes, and evolutionary outcomes are theorized to be constrained by the 
criteria of achieving increased fitness. Yet, differences in the persistence of populations, 
and their resulting sizes can also be explained by the necessity to conform to the 
thermodynamic principles that govern energy infrastructures within biological systems.
The direction of evolution is driven by the minimization of the total Gibb’s free energy in 
a system. This minimal energy criterion is contingent upon the second law of 
thermodynamics, which favors entropy maximization (Jia, Liggins, & Chow, 2014).
Disparities in thermodynamic fitness, which may arise from interactions among various 
factors including environment and phenotype, can prompt adaptive responses from other
components within a system in order to maintain overall thermodynamic stability.
If the evolutionary constraints exerted upon the system persist and are quite
strong, compensatory responses may also be conserved over time within a population.
One example of a molecular system that is not exempt from the principle of minimal 
energy is membrane proteins. The unfavorable interactions between the termini of 
membrane protein dipoles and their electrically charged environments may be recognized
by protein selection and insertion machinery (Agnati et al., 2005). As a result, proteins 
with greater stabilizing characteristics, such as high hydrophobic energies, may be
selected for insertion within the hydrocarbon cores of cellular membranes in order to
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compensate for their otherwise high instabilities. However, few studies have investigated
this hypothesis.
Understanding the thermodynamics underlying membrane protein stability is 
desirable for many reasons. Membrane proteins account for roughly one-third of all
sequenced proteins and are one of the most important features of cellular systems (Hubert 
et al., 2010). These proteins play diverse roles in the normal functioning of cells and are
involved in various functions, including cell-cell adhesion, molecular transport, ion 
regulation, signal transduction, enzyme catalysis, and immune pathways. Since 
membrane proteins are key components of cellular defense pathways, a fundamental
understanding of the thermodynamic mechanisms underlying their stability and
functioning is essential to drug development initiatives. In fact, bitopic membrane 
proteins account for more than 60% of all known drug targets encoded by the human 
genome (Yin & Flynn, 2016).
Currently, most exogenous agonists are designed to inhibit, activate, or modify
cell signaling pathways by selectively binding to protein moieties acting as cell-surface
receptors and subsequently triggering or suppressing associated effector and second
messenger cascades. Therapeutic ligands are designed to adhere exclusively to exposed
peptide regions that are easily accessible on the surface of the bilayer. In fact, G-protein 
coupled receptors account for one-third of drug targets (Dror et al., 2011). Yet, 
therapeutic agents are seldom designed to directly target transmembrane domains 
embedded deep in the interior of the hydrophobic bilayer.
The tendency to develop therapeutics that target exposed protein segments instead
of those that target protein segments embedded within the bilayer’s hydrophobic core can
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be attributed to several factors. First, the process of accessing the hydrophobic core of
the plasma membrane is experimentally complex and often difficult to achieve. Steroids 
and small nonpolar molecules characterized by high permeability are able to passively
diffuse across the transmembrane region of the bilayer, but the passage of the majority of
large polar molecules involves transport-mediated or endocytic pathways. Although not 
altogether impossible, the translocation of proteins and small peptides across membranes
is rare (Yang & Hinner, 2016). Another perceived barrier to the viability of 
transmembrane drug targets is that drug targets require high specificity, but it is still
unknown which specific regions of the transmembrane region could serve as potential
drug targets.
Second, the erroneous concept that transmembrane domains serve no other
purpose than to anchor the protein within the bilayer is, unfortunately, quite prevalent. 
The idea that transmembrane domains do not engage in meaningful interactions that are
subject to drug targeting still informs much of the development of biopharmaceuticals. 
This notion is gradually changing as experimental evidence is accumulating that shows 
the functional importance of transmembrane domains. Nevertheless, the properties of 
transmembrane domains involved in disease pathways has remained relatively
underexplored compared to the attention that has been paid to their extracellular
counterparts.  Experiments examining the extent to which the hydrophobicities of 
transmembrane helices serve as an energetic hindrance to retrotranslocation by
endoplasmic reticulum associated degradation (ERAD) pathways during protein 
misfolding have been performed, but information regarding the general mechanism and
details underlying transmembrane domain removal from the bilayer preceding
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degradation is scarce (Guerriero et al., 2017).  Exacerbating the inattention to 
transmembrane drug targets is the dearth of available information on membrane protein 
three-dimensional structure (Opella & Marassi, 2004). In fact, only 2% of structures in 
the Protein Database Bank belong to membrane proteins (Zhou, Zheng, & Zhou, 2004). 
Ultimately, the reality remains that the number of available extracellular drug targets 
encoded by the human genome is finite. When pharmacotherapy has exhausted the study
of extracellular drug targets, the pressure and the demand for the study and identification
of novel drug targets and their biophysical properties will inevitably increase.
In spite of the biases underlying drug research, the advancement of existing and 
novel biotechnological methods is helping to redefine the notion of what makes
molecular moieties targetable. Advances in X-ray crystallography, cryoelectron 
microscopy, and nuclear magnetic resonance spectroscopy are contributing to the 
growing database of available membrane protein structures and protein-protein
interactions and could greatly help to inform structure-based rational design (Punta et al.,
 
2007). The refinement of ToxR, an experimental method that probes interactions among 
transmembrane domains, is another promising advancement in the quest for information 
on transmembrane domain interactions. In addition, the discovery of highly specific and
localized protein-protein interaction hot spots has encouraged the development of drugs
that exclusively target these critical areas. The novel synthesis of molecular mimics that
influence transmembrane domain-domain interactions also represents an alternative 
method of drug delivery. For example, small molecules have been identified that target
Toll-like Receptor one and two, a key player in Parkinson’s disease.
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In light of the evolving definition of what constitutes a good drug target and the 
rapid pace of biotechnological development, research on the fundamental properties of 
transmembrane domains is essential. It is incumbent upon the scientific community to 
ensure that the availability of information on transmembrane domains and the 
interactions among them progresses at a rate equal to that of biotechnological advances. 
In anticipation of the emerging need for more information on the physicochemical
properties of transmembrane domains, we performed a comparative study that
characterizes the stabilizing properties of transmembrane proteins, namely the 
hydrophobic free energies of their hydrophobic domains. In this study, we identified
statistical differences between the hydrophobic free energies and Shannon entropies of 
two groups of bitopic proteins. A weak correlation between hydrophobic free energies
and Shannon entropies was determined, and further research is needed in order to 













Type I and Type II Proteins
 
Membrane proteins are proteins that are embedded in the plasma membrane, a 
lipid bilayer that serves as a selectively permeable barrier between the interior cellular 
environment and the surrounding extracellular space. Two classes of membrane proteins 
are peripheral and integral membrane proteins. Peripheral membrane proteins are water-
soluble proteins that are attached to the exterior surface of the plasma membrane, while 
integral membrane proteins are proteins that have one or more regions embedded in the 
hydrophobic core of the lipid bilayer. Integral membrane proteins that have backbones
that transverse the entire length of the phospholipid bilayer are called transmembrane 
proteins (Cooper, 2000). Transmembrane proteins consist of bitopic and polytopic
proteins. Bitopic proteins cross the bilayer only once. Examples of bitopic proteins 
include Type I, Type II, and Type III proteins. Polytopic proteins, such as Type IV
proteins, cross the bilayer more than once (Zviling, Kochva, & Arkin, 2007).
Type I and Type II TM proteins are polymers composed of individual monomeric 
amino acid units held together by peptide bonds. They typically exist as a distinct type of 
secondary structure protein called an alpha helix and assume the three-dimensional shape 
of a coil or a screw that is held together by hydrogen bonds (Albers, 1999). In terms of 
chirality, most alpha helical proteins are right handed (Cole & Bystroff, 2009). Type I
membrane proteins are characterized by a signal peptide sequence that is approximately
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15 hydrophobic amino acid residues in length and is subsequently cleaved from the rest 
of the peptide. The signal that cues the protein to remain embedded in the membrane 
instead of being completely threaded through is called a stop-transfer sequence, which is 
composed of approximately 20 hydrophobic amino acid residues. The signal peptide 
sequence and the stop transfer sequence result in the translocation of the peptide’s N-
terminus across the membrane.
In contrast to Type I membrane proteins, Type II membrane proteins contain a 
signal-anchor sequence that is approximately 25 hydrophobic amino acid residues in 
length and are much longer than Type I signal sequences. Type II signal-anchor 
sequences are characterized by the absence of a signal peptidase cleavage site and are
therefore not cleaved after translocation occurs. Type II signal-anchor sequences result in 
the translocation of the peptide’s C-terminus across the membrane. Type I proteins have 
their positively-charged amino group oriented towards to the extracellular space while 
their negatively-charged carboxyl groups are oriented towards the cytoplasmic interface.
Type II proteins have their negatively-charged carboxyl groups oriented towards the 
extracellular space, while their positively-charged amino groups are oriented towards the 
cytoplasmic compartment. Thus, Type I and Type II proteins are opposites of each other
in terms of their orientations within the membrane (Goder & Spiess, 2001).
The Alpha Helix Dipole
 
Peptide bonds within Type I and Type II proteins produce individual dipoles. Each 
protein has a net dipole moment with two polarized termini that is calculated from the
sum of the individual dipole moments of peptide bonds (Moran, Horton, Scrimgeour, & 
Perry, 2011). A dipole moment is a vector value that quantifies and describes the
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electrical polarity of a molecule. A dipole moment is formed when a molecule contains 
atomic regions that possess a partial positive or partial negative charge and are spatially
arranged in such a way so that they do not cancel one other out. Electronegativity is a 
measure of an atom’s affinity for electrons in a bond, and unequal charge distributions in 
a molecule arise due to differences in the electronegativities of the individual atoms 
comprising that molecule. Dipole moments can occur in both diatomic and polyatomic 
molecules. In a diatomic molecule containing two covalently bonded atoms possessing 
unequal electronegativities, the more electronegative atom will attract electrons 
(negatively charged particles) to itself and acquire a partial negative charge, while the 
less electronegative atom will acquire a partial positive charge. In general, a dipole
moment can be calculated using the following equation: μ=q x r, where μ is the size of 
the dipole moment, q is the charge, and r is the distance of separation between the two 
charges. The unit symbol of a dipole moment is D, which stands for units of Debye. In
artistic renderings, the dipole moment can be drawn as an arrow with a cross tail. While
many chemistry textbooks render the tip of the arrow to denote the negative pole and the 
crossed tail to denote the positive pole, physics conventions use IUPAC nomenclature 
and represent the tip of the arrow as the positive pole and the crossed tail as the negative 
pole (Parkanyi, 1998).
Proteins are composed of amino acids joined by a peptide bond, a type of covalent 
bond.  Each amino acid is composed of an alpha carbon, a hydrogen, a unique side chain 
residue, an amino group (-NH2), and a carboxyl group (-COOH). A dehydration
synthesis reaction produces a peptide bond between two individual amino acids and 
releases a water molecule. At physiological pH, amino acids exist as zwitterions, and
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their structures are represented differently from their representations in theoretical
reactions, but the process is relatively the same. In the theoretical condensation reaction,
the lone pair of electrons on the nitrogen of the amino group will perform a nucleophilic
attack on the carbon of the carboxyl group. As a result, the pre-existing lone pair of 
electrons on the nitrogen will form a new bond between the amide nitrogen and the 
carbonyl carbon. This results in carbon having 10 valence electrons, which violates the 
octet rule, which leads to the hydroxyl (-OH) that comprises the carboxyl group on the 
first amino acid being protonated when it binds to a hydrogen in the amino group of the 
second amino acid. The -OH will remove the two electrons it originally shared with 
carbon and use them to form a bond to a hydrogen of the second amino acid. The 
combination of -OH and -H forms a water molecule. The lone pair of valence electrons 
that is left by the hydrogen may either: continue to exist as a lone pair on the nitrogen or 
form a second bond between the nitrogen and the carbon, which creates partial double
bond character to the N-C of the peptide bond; this delocalization of electrons is called
resonance. Apart from the structural stability that it confers to a peptide bond, resonance
paradoxically also confers stereochemical variation. Since the amide nitrogen’s electrons 
are delocalized, the dipeptide segment is a stereoisomer that can assume one of two
isomeric forms (cis- or trans-) in three-dimensional space. The cis- isomer is when the 
functional groups are on the same side, while the trans- isomer is when the functional
groups are on opposite sides. At physiological conditions, the majority of dipeptide 
segments exist in the trans- form. When dipeptide segments exist in a trans orientation, 
the arrangement of atoms permits a dipole to form.
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A peptide bond’s dipole moment is due to differences in electronegativity between
two pairs of atoms. The first pair of atoms is the oxygen and the carbon in the amino
acid’s carbonyl group.  Since oxygen’s electronegativity is greater than that of carbon,
the oxygen will assume a partial negative charge (-0.42) and the carbon will assume a
partial positive charge (+0.42). The second pair of atoms is the nitrogen and the 
hydrogen in the amino acid’s amino group.  Since nitrogen’s electronegativity is greater
than that of hydrogen, the nitrogen will assume a partial negative charge (-0.20) and the 
hydrogen will assume a partial positive charge (+0.20). Both dipole moments formed by
each pair of atoms exist parallel to the helix axis. In addition, the alpha helix contains 
three types of torsional angles: , and .  Ramachandran plots are plots of the (phi) 
angles against (psi) angles; the presence of clusters indicates that a helix possesses 
a regular repeating structure. Since Ramachandran plots indicate that the a angles
of each amino acid in a helix are very similar (-57º and -47º, respectively), the alpha helix
exhibits structural regularity. Structural regularity is vital to preventing the disruption of
a helix’s net dipole moment.  Since the alpha helix is composed of 3.6 residues per turn
and contains multiple repeating turns depending on its length, it contains multiple peptide 
bonds. The individual dipole moments of each peptide bond will result in a net dipole 
moment called a macrodipole with charged terminal ends, where the amino terminus is 
positive and carboxyl terminus is negative. Since the dipole moment of a single peptide 
bond is 3.6 D, the macrodipole of an alpha helix can be calculated as the number of
amino acid residues times 3.6 D.
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Electrical Properties of Cellular Membranes
 
Cellular systems are characterized by the presence of an electrical gradient at the 
membrane boundary. These electrical gradients confer a positive charge along the 
membrane-extracellular space (ECS) interface and a negative charge along the 
membrane-cytoplasm interface. This electrical gradient is called membrane potential, 
which is analogous to an electromagnetic field. When magnetic dipoles are placed in 
electric fields, their energetic stability may be high or low. Similarly, when TM proteins 
are placed within membranes having membrane potential, their energetic stabilities may
be disrupted or enhanced due to the interactions between the voltage gradient and the 
charged dipole termini of native proteins (Figure 1).
 





The difference in the orientations of Type I and Type II membranes suggests that 
there is also a difference in electrical energy between these two transmembrane proteins. 
Type I proteins may exhibit greater thermodynamic instability due to the interactions 
between their negatively-charged carboxyl groups and the negatively charged membrane-
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cytoplasm interface. Type II proteins may exhibit less thermodynamic instability due to 
the interactions between their positively-charged amino groups and the positively-
charged membrane-ECS interface. This observation is based on Coulomb’s law, which
simply states that oppositely charged particles tend to attract, while similarly charged
particles tend to repel. These principles are illustrated by potential energy curves, which
demonstrate that as the distance between like-charges decreases (as they move closer
together), their repulsive potential energy increases; however, as the distance between
opposite charges decreases (as they move closer), their repulsive potential energy
decreases.
It is possible to measure the strength of attractive and repulsive forces using
Coulomb’s law, which measures the strength of the force/energy between a pair of 
charges in joules (J). Attractive forces are indicated by negative signs (gained by the
product of two opposite charges), while repulsive forces are indicated by positive signs (a 
result of the product of two similar charges). In the following formula, k is a constant of
2.31 x 10-19 J Q1 and Q2 represent the quantities of the charges on each respective
 






The degree of a force (whether attractive or repulsive) between two atoms is the product
of the two charges on both atoms divided by measure of the distance between them 
multiplied by the constant, k. Thus, as a result of this biophysical dynamic, Type I
proteins may exhibit greater electrochemical instability. The former situation results in 
greater thermodynamic stability, while the latter situation results in lower thermodynamic
instability. Since the configurations of Type I proteins represent the latter situation, they
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are, in effect, at a greater energy disadvantage due to their orientation within cellular 
membranes.
Determinants of Protein Stability
 
The properties of lipid bilayers that surround membrane proteins are one of the 
determinants of membrane protein stability are the properties of the lipid bilayers that 
surround membrane proteins (Van Klompenburg, Nilsson, von Heijne, & de Kruijff,
1997).  Unlike the substances that solvate globular proteins, the lipid medium is far from 
isotropic. The plasma membrane is composed of a variety of different lipids, and certain 
types of lipids are more abundant in certain areas of the bilayer. For example, the 
extracellular outer leaflet usually contains high amounts of sphingolipids, glycolipids, 
and phosphatidylcholine, while the cytoplasmic inner leaflet usually contains 
phosphatidylserine, phosphatidylethanolamine, and phosphatidylinositol. Some lipids, 
such as cholesterol, are evenly distributed throughout both layers and may cause 
fluctuations in the permeability of the membrane. Such disruptions to membrane
permeability may influence protein stability. The disparities in regional lipid composition 
along a membrane may primarily be attributed to the presence of lipid rafts. Lipid rafts 
are lipid-dense areas along the plasma membrane that contain localized and unique 
concentrations of sphingolipids, cholesterol, and proteins (Pike, 2003). The ability of 
components to be recruited to or disassociate from lipid rafts and the ability of rafts to 
move laterally and combine with other rafts (in a process called raft clustering) make the 
lipid composition of these areas highly dynamic.
The high variety of lipids that comprise membranes may be due to the 
corresponding diversity of proteins that they solvate and the interactions that occur
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between them amidst fluctuations in temperature, osmolarity, pH, and supramolecular 
lipid polymorphisms (Simons & Sampaio, 2011). A membrane protein’s ability to 
function depends on the presence of particular lipids having specific head groups or
hydrocarbon tails that may serve to optimize its functionality (Deol, Bond, Domene, &
Sansom, 2004). Furthermore, the chemical composition of a lipid membrane encasing a 
particular organelle may be very different from those of other organelles. Studies have 
also found that the electrostatic properties of membrane voltage gradients are dependent 
upon the compositions of the lipids that generate them (Gurtovenko & Vattulainen, 2008).
Similarly, the lengths of lipids that comprise the membrane help determine the thickness
of the phospholipid bilayer (Lee, 2004).  On average, the polar headgroups of lipids are
15 Å, and their hydrophobic regions are 30Å (Haltia & Freire, 1995). Yet, differences in 
lipid composition in certain regions of the bilayer may result in variations in membrane 
thickness along the circumference of the cell (Nagle & Tristram-Nagle, 2000). It has
been shown that fluctuations in temperature may affect lipid thickness as well (Simon,
Advani, & McIntosh, 1995).
Apart from influencing the electrostatic gradients across membranes, variations in
the thickness of the bilayer are important, since it may also affect the angle at which a 
membrane protein is tilted perpendicular to the membrane plane (Kim & Im, 2010). 
Multiple studies have shown that when bilayer thickness is shortened, protein tilt angle
— the angle formed by the protein and the axis perpendicular to the membrane plane —
increases (Holt et al., 2009). The biological phenomenon in which a discrepancy exists
between the length of the transmembrane helix and membrane thickness is called
hydrophobic mismatch (de Jesus & Allen, 2013). Changes in tilt angle in response to the
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shortening of the bilayer occur in order to optimize the retention of the peptide’s
transmembrane helix and hydrophobic residues within the hydrophobic core (Park &
Opella, 2005). In addition, it has also been observed that helices may bend and stretch in 
response to hydrophobic mismatch (de Jesus & Allen, 2013).
Hydrophobicity Scales
 
Hydrophobicity is a quantitative measure used to determine how anchored a 
protein is within the membrane. Hydrophobicities are represented as GRAVY values and
are computed as the average of the hydrophobicities of each amino acid within a 
polypeptide sequence. A hydrophobicity scale assigns a hydropathy value to each of the
20 amino acids. Several hydrophobicity scales are available, and each scale is 
constructed using different methods. The Kyte and Doolittle (KD) hydrophobicity scale
is one of the most widely used hydropathy scales in the field of biophysics (Appendix A).
In the Kyte and Doolittle scale, the majority of the hydropathy values for each individual 
amino acid were determined by averaging two or three normalized values (Kyte &
Doolittle, 1982). The first value is the transfer free energies from water to vapor
G°water vapor) in kcal/mol. This value was used in lieu of the transfer free energies 
from water to ethanol and ethanol to vapor, due to the non-neutral properties of ethanol. 
The water-vapor transfer partition coefficients were based on model substances
equivalent to each amino acid residue and represent a compilation of data collected by
scientists including Hine and Mookerjee (1975) and Wolfenden, Cullis, & Southgate 
(1979).  Chothia (1976) used twelve globular native structures and their coordinates to 
record the number of times a particular amino acid residue was found to be 95% buried
within the interior of the protein. This value was then divided by the total number of that
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occurring residue. Thus, the second value is the fraction of residues that are 95% buried,
and the third value is the fraction of residues that are 100% buried.
Functional Significance of Transmembrane Domains
 
Apart from securing membrane proteins in the bilayer, transmembrane domains 
play many important roles in the biological and biochemical functions of proteins 
involved in disease pathways. For example, mutations in the third transmembrane 
domain of the melanocortin-4 receptor (MC4R) – a G protein-coupled receptor, that has
been identified as a cause of obesity – significantly affect ligand binding, signaling, and
second messenger production (Mo, Yang, & Tao, 2012). Similarly, experiments have 
shown that transmembrane domains of a viral membrane protein called LMP-1 are 
primarily involved in signaling activity of the Epstein-Barr virus (Kaykas, Worringer, &
Sugden, 2002). It has been found that mutations in transmembrane domains of the 
diphtheria fusion protein toxin DAB3890-IL-2 can alter cytotoxicity (VanderSpek,
Mindell, Finkelstein, & Murphy, 1993).  Mutations in transmembrane domains of 
penicillin binding proteins in S. pneumoniae have given rise to morphological
modifications in cells, which shows the importance of transmembrane domains in
peptidoglycan construction (Berg et al., 2014).  Furthermore, the transmembrane domains 
of a kidney-lung sodium channel complex are responsible for indicating degradation by
endoplasmic reticulum chaperones (Buck et al., 2017). In addition, transmembrane 
domains have also been found to facilitate the dimerization of toll-like receptor (TLR)
proteins (Godfroy, Roostan, Moroz, Korendocych, & Yin, 2012).  Other scientists have 
found that survival proteins mediate apoptosis inducing proteins, such as Bax, through
transmembrane domain mediated associations (Andreau-Fernandez, 2017).
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Transmembrane domains are also known to influence the energetic interactions 
within cells. The transmembrane domain of the Influenza A viral M2 proton channel is
responsible for proton translocation (Hu et al., 2007). Transmembrane domains also have 
biophysical implications on the characteristics of membrane proteins. For example, the 
macrodipole of transmembrane proteins significantly contributes to the ability of proteins 
to participate in helix-bundle aggregation and their transport capabilities. Helices that 
comprise a bundle are often positioned antiparallel to one another due to the increased
stabilization that is conferred. In turn, aggregation and orientation can greatly influence
the variable functional capabilities of the membrane proteins and those of the aggregates 
that they form (Brady, Siegel, Albers, & Price, 2012).  Hence, transmembrane domains















Retrieval of Type I and Type II Protein Accession Numbers
 
Type I and Type II membrane proteins and their accession numbers were retrieved
from UniProtKB (http://www.uniprot.org). Lists for all Type I and Type II proteins were 
located by setting the filter function to display proteins by “subcellular location” and
inputting “single-pass” in the search bar on the database’s home page.  Proteins were 
sorted by type and stored in Excel spreadsheets. Only proteins that were Swiss-Prot 
manually annotated and reviewed (via experimental research or computerized prediction 
models) were selected in order to maintain quality assurance. Proteins found in
organisms other than Homo sapiens were excluded from this study. Only proteins 
residing in the plasma membrane were retained.
Retrieval of Transmembrane Domain Residue Sequences
 
Amino acid sequences comprising the transmembrane regions of all Type I and
Type II alpha helical proteins were individually retrieved from each of the protein profiles
contained in UniProtKB. Retrieval was accomplished by accessing a particular protein’s
profile and selecting the “Subcellular Location” tab on the leftmost menu bar shown on 
the subsequent interface. The residue sequence was obtained by locating the
“Position(s)” column and selecting the range of position numbers displayed adjacent to
the “Transmembrane” row in the “Feature Key Table” that is included in the “Topology”
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subsection of the protein’s profile. All residue sequences were transferred to Excel
spreadsheets and stored alongside their corresponding accession numbers.
Retrieval of Grand Average of Hydropathicity Values
 
Manually computed Grand Average of Hydropathicity (GRAVY) values were 
validated externally using the integrative ProtParam software tool from the SIB ExPASy
(Expert Protein Analysis System) Bioinformatics Resource Portal. This is a
supplementary portal that can be accessed from within the UniProtKB database. Within 
any given protein profile, the “Sequence” tab was selected from the left menu bar and the 
“ProtParam” option was selected from the dropdown menu bar. The range for a sequence
fragment corresponding to “FT TRANSMEM” was selected.  Only peptide sequence
fragments with endpoints designated “TRANSMEM” were selected for physicochemical
properties analysis. The GRAVY value was obtained by locating the computed parameter
on the protein analysis interface. ExPASy ProtParam GRAVY values were matched
against computed values (based on the same Kyte-Doolittle hydropathy scale) in order to 
identify errors and inconsistencies in computed values.
Retrieval of Kyte and Doolittle Hydropathy Indices
 
The Kyte and Doolittle hydropathy indices for all amino acids were obtained by
accessing the ExPASy portal’s ProtScale tool (http://www.expasy.org) and selecting the 
“Hphob. / Kyte & Doolittle amino acid scale” from the list of available scales.  Each
amino acid’s hydropathy index was imported into Excel. Hydropathy values were 
validated by directly accessing the original article.
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Retrieval and Determination of Protein Functional Class
 
Functional classes of all proteins were determined by accessing a particular
protein’s profile and selecting the “Function” tab on the leftmost menu bar shown on the 
interface of each individual UniprotKb protein profile. All known molecular and
biological functions of each protein were retrieved from the “Function” subsection.
Enzymatic functions and pathways were retrieved from Reactome, a peer-reviewed
external database that can be accessed through UniprotKb (http://www.reactome.org). 
Proteins were classified into one or more of the following functional categories: Enzyme,
Receptor, Both Enzyme and Receptor, Immune, Both Immune and Receptor, Transporter,
and Other. The function(s) of proteins belonging to the category “Other” were recorded
in a separate column.
Mathematical Computation
 
Computation of Gibb’s Free Energy
 
The electrical free energies G°) of the dipoles of Type I and Type II alpha
helices in the charged membrane field were calculated using the electrical free energy
equation: G = μE where μ is the dipole moment charge (1 electron) multiplied by the 
electron charge (1.6 x 10-19 C) multiplied by the length of the helix (Lh).  E is the 
membrane potential (Vm) divided by the thickness of the membrane (Lm). Here, we make 
the following assumptions: 1) The length of each helix approximates the thickness of the 
portion of the membrane it is embedded in, 2) membrane potential is 100 mV.
Computation of Hydrophobic Energies
Following residue sequence retrieval, the hydrophobicity values of all Type I and
 
Type II proteins were manually calculated using UniprotKb. Sequences were
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manipulated in Excel and treated as text strings. Alphabet characters comprising each
text string sequence were horizontally divided into individual cells. The “text to
columns” feature was used to set field widths and create column breaks so that a single 
letter representing a single amino acid was assigned to a solitary cell. Subsequently,
individual hydropathy indices for all 20 amino acids based on the Kyte-Doolittle scale 
(Appendix A) were imported from ExPASy and assigned to their corresponding amino
acid symbol in Excel. All amino acids were replaced with their corresponding scale
values using the “substitution” feature.  GRAVY values for all proteins were calculated as
the average (the sum of the hydropathy values of all constituent amino acids divided by
the number of residues in the sequence) of each alpha helix’s amino acid constituents. 
GRAVY values were then multiplied by the number of amino acid residues in each
protein’s transmembrane domain. GRAVY values were converted from units of kcal/mol 
to units of kJ/mol.
Computation of Shannon Entropies
 
Information entropies of both groups of transmembrane proteins were determined
and compared. The following formula was used to compute Shannon entropies (SE): SE
= - Plog2P, where P is the probability of a given amino acid within a given protein’s
residue sequence. Amino acid text sequences were converted to columns and column
breaks were inserted. The “substitution” feature was used to replace each amino acid 
letter symbol with the number 1, and the “=SUM” formula was used to compute the 
number of times an amino acid appeared within a given sequence. Once the frequency of 
appearance was calculated, the 1s were replaced with the amino acid letter symbol once 
more. As a precautionary measure, the number zero was used to replace all ones in order
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to ensure that if ones were not replaced with their amino acid letter symbol for any
reason, that the retained ones would not affect the subsequent frequencies of the next
amino acid being summed. This procedure was performed for all 20 amino acids for all
proteins. Once the frequencies of all amino acids were calculated, the lengths of each
sequence was calculated using the “=LEN(first cell, last cell)” formula. The probability
value of each amino acid was computed by dividing the amino acid frequencies by the
length of the entire protein. In order to achieve this, the conditional formula function
“=IF(probability = 0, 0, probability *(LOG(probability, 2)))” was used. Following this
step, the “pLog2P” amino acid values for each row were summed to yield the Shannon
entropies of each transmembrane protein.
Statistical Analysis
 
Monte Carlo Simulation of Normal Distribution of Hydrophobic Energies
 
A random number generator in Excel was used to generate 10,000 random 
transmembrane amino acid residue sequences. Hydrophobic energies for each sequence
was calculated, and a frequency distribution of all sequence hydrophobic energies was
created in order to ensure that the hydrophobic energies of the random sequences were 
normally distributed.
Shapiro Wilk Test of Gaussian Normality of Hydrophobic Energies
 
In order to determine if the assumption of normality required by the Student’s t 
test were met by the data, Statistical Package for the Social Sciences (SPSS) software 
was used to perform a Shapiro Wilk test. Both Type I and Type II proteins along with 
their respective hydrophobic energies were transferred to a new data sheet in SPSS. The 
“Analyze” tab was selected from the top menu bar, and the “Explore” function was
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selected. Type was moved to the “Factor List” space and Hydrophobic Energy was
moved to the “Dependent List.” The “Statistics” tab was opened and used to set the 
“Confidence Interval for the Mean” to 95%. Only the “Descriptives” box was checked.
The “Plots” tab was opened and “Normality plots with tests” was checked. No changes
were made to the “Options” criteria. As a supplement to the Shapiro Wilk test, 
histograms showing the frequency distributions of both Type I and Type II protein 
hydrophobic energies were created in order to provide a secondary visual measure with 
which to assess the data. To create the histograms, Minitab software was used. The data
was transferred into a new spreadsheet, and the “Graphs” tab was used to generate the 
histograms.
Levene’s Test of Equality of Variances of Hydrophobic Energies
 
In order to determine if the assumption of equal variances required by the 
Student’s T test were met by the data, SPSS was also used to perform a Levene’s Test for 
homogeneity of variances. A Levene’s test for homogeneity of variances was conducted
using a “One-Way ANOVA” where default settings for “Contrasts” and Post Hoc 
Criteria” were used.
Mann-Whitney U Test of Hydrophobic Energies
 
Following the validation of the assumptions required by the parametric Student’s
T test, SPSS was used to perform a non-parametric Mann-Whitney U test in order to 
determine whether or not there exists a statistically significant difference between the 
hydrophobic energies of Type I and Type II protein groups. The “Analyze” tab was
selected from the top menu bar, “Nonparametric Tests and Legacy Dialogs” were 




variables were organized and each group was defined as one and two, respectively. In the 
“Options” criteria, “Descriptives and MWU” were selected.  Given n1=1118, n2=155, and 
the Sum of Ranks = 726967.50, the following formulas were used to derive the U test
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The value that was selected to be compared to the U-critical value is the smaller of U1
 
and U2; thus, U1 was retained.
 
Z Test of Hydrophobic Energies
In order to perform a Z test, the Z-test statistic of the hydrophobic energies was
derived using the following formula:
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Monte Carlo Simulation of Normal Distribution of Shannon Entropies
 
A random number generator in Excel was used to generate 10,000 random 
transmembrane amino acid residue sequences. Shannon entropies for each sequence was
calculated, and a frequency distribution of all sequence Shannon entropies was created in 




Shapiro Wilk Test of Gaussian Normality of Shannon Entropies
 
In order to determine if the assumption of normality required by the Student’s T
test was met by the Shannon entropies of Type I and Type II proteins, SPSS software was
used to perform a Shapiro Wilk test. The “Analyze” tab was selected from the top menu 
bar, and the “Explore” function was selected. “Type” was moved to the “Factor List”
space and “Shannon Entropy” was moved to the “Dependent List.” The “Statistics” tab 
was opened and used to set the “Confidence Interval for the Mean” to 95%. Only the 
“Descriptives” box was checked. The “Plots” tab was opened and “Normality plots with 
tests” were checked. No changes were made to the “Options” criteria. As a supplement 
to the Shapiro Wilk test, histograms showing the frequency distributions of both Type I
and Type II protein Shannon entropies were created in order to provide a secondary
visual measure with which to assess the data.  Histograms were created using Minitab. 
Levene’s Test of Equality of Variances of Shannon Entropies
A Levene’s test of homogeneity of variances (SPSS) was used to determine if the 
assumptions of equal variances required by the Student’s T test was met by the Shannon 
entropies of Type I and Type II proteins. The “Analyze” tab was selected from the top 
menu bar, the “Compare Means” function was selected, and a “One-Way ANOVA” was
performed. No changes were made to the “Contrasts and Post Hoc criteria.” Under
“Options,” “Homogeneity of Variances” was selected.
Mann-Whitney U Test of Shannon Entropies
 
Following the validation of the assumptions required by the parametric Student’s
T test, SPSS was used to perform a non-parametric Mann-Whitney U test in order to 




Shannon entropies of Type I and Type II protein groups. The “Analyze” tab was selected
from the top menu bar, “Nonparametric Tests” and “Legacy Dialogs” were selected, and a
“2 Independent Samples Test” was performed. Test and grouping variables were 
organized and each group was defined as one and two, respectively. In the “Options”
criteria, “Descriptives and Mann-Whitney U test” were selected. Given n1=1118, n2=155,
and the Sum of Ranks = 690642.50, the following formulas were used to derive the U-





n (n +1) U =n n + 1   1  - Sum of Ranks
1 1  2 2
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The value that was selected to be compared to the U-critical value is the smaller of U1
 
and U2; thus, U2 was retained.
Z Test of Shannon Entropies
In order to perform a Z test, the Z-test statistic of the Shannon entropies was
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Linear Regression of Hydrophobic Energies and Shannon Entropies
 
Shannon entropies of both Type I and Type II proteins were regressed against the 
transmembrane domain hydrophobic energies of both Type I and Type II proteins, 












Gibb’s Free Energy Difference
 
The Gibb’s free energy of Type I proteins was calculated to be 4.816 kJ/mol, and 
the Gibb’s free energy of Type II proteins was calculated to be -4.816 kJ/mol. The total
difference in electrical free energy ( G°) stability between and Type I and Type II 




Gtype1° = [(0.5 e) x (1.6 x 10-19 C / 1 e) x (0.1V) x (6.02 x 1023/mol)] x (10-3 kJ/J)] 
Gtype1° = 4.816 kJ/mol
Gtype2° = -[(0.5 e) x (1.6 x 10-19 C / 1 e) x (0.1V) x (6.02 x 1023/mol)] x (10-3 kJ/J)] 
Gtype2° = -4.816 kJ/mol
G° = Gtype1° - Gtype2° G° =
4.816 kJ/mol – -4.816 kJ/mol G° =
9.63 kJ/mol
Frequency Distributions of Hydrophobic Energies
 
Histograms were constructed to provide preliminary and alternative visual 
assessment of the frequency distributions of hydrophobic energies for both groups of
proteins (Figures 2 and 3). Type I mean hydrophobic energy was calculated to be 231.6 
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Figure 3. Frequency distribution of Type II TM protein hydrophobic energies
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Mann-Whitney U Test of Hydrophobic Energies
 
The results of the Shapiro Wilk test show that both Type I and Type II protein 
groups violate the assumption of normality required by the Student’s T test. This is
indicated by the fact that the p values yielded by the Shapiro Wilk test using an = 0.05
for Type I and Type II protein groups are both significant (p = 0.000 and 0.017,
respectively). The results of the Levene’s test show that the data for Type I and Type II 
protein groups violate the assumption of homogeneity of variances required by the 
Student’s T test, given an alpha value of 0.05. This is indicated by the fact that the p
value yielded by the one-way ANOVA is less than 0.05. The Levene’s test yielded a p
value of 0.038. The descriptive statistics yielded a variance of 1749.9 and 2288.8 for 
Type I and Type II proteins, respectively. The results of the Mann-Whitney U test show 
that the mean ranks of Type I and Type II proteins are 650.24 and 541.51, respectively
(Table 1). The Mann-Whitney U Test that was performed in SPSS yielded a two-tailed 
asymptotic p value of 0.001 (Table 2), while the one-tailed test which was performed in 
Minitab yielded a significant p value of 0.0003 assuming a confidence level of 95%
(Table 3).
 
n (n +1) U =n n + 1   1  - Sum of Ranks
1 1  2 2
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Table 1. Mean ranks of Type I and Type II TM protein hydrophobic energies
 
 
Table 2. Asymptotic two-tailed p value of Mann-Whitney U test of hydrophobic energies
 
Mann-Whitney Test and CI: T1 Hydro, T2 Hydro
 N Median
T1 Hydrophobicity 1118 55.650
T2 Hydrophobicity 155 53.200
Point estimate for 1 - 2 is 3.200
 
95.0 Percent CI for 1 - 2 is (1.400, 4.999) 
W = 726967.5
Test of 1 = 2 vs 1 < 2 is significant at 0.0003
 








Z Test of Hydrophobic Energies
 
The results of the two independent sample Z test on the mean hydrophobic 
energies of Type I and Type II proteins yielded a standard deviation of 2389.2 and a Z-
test statistic of -3.4510, which corresponds to a p value of 0.0003, given n1=1118,
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Frequency Distributions of Shannon Entropies
 
Histograms were constructed to provide preliminary and alternative visual 
assessment of the frequency distributions for both groups of proteins (Figures 4 and 5). 
Type I mean Shannon entropy was calculated to be 2.560 bits, while Type II mean
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Figure 5. Frequency distribution of Type II TM protein Shannon entropies
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Mann-Whitney U Test of Shannon Entropies
 
The results of the Shapiro Wilk test show that both Type I and Type II protein 
groups violate the assumption of normality required by the Student’s T test. This is
indicated by the fact that the p values yielded by the Shapiro Wilk test using = 0.05 for 
Type I and Type II protein groups are both significant (p = 0.000 and 0.000, respectively). 
The results of the Levene’s test show that the data for Type I and Type II protein groups 
violate the assumption of homogeneity of variances required by the Student’s T test,
given an alpha value of 0.05. This is indicated by the fact that the p value yielded by the
one way ANOVA is less than 0.05. The Levene’s test yielded a p-value of 0.000. The 
descriptive statistics yielded a variance of 0.078 and 0.196 for Type I and Type II 
proteins, respectively. The results of the Mann-Whitney U test show that the mean ranks 
of Type I and Type II Shannon entropies are 617.75 and 775.86 respectively (Table 4). 
The Mann-Whitney U test that was performed in SPSS yielded a two-tailed asymptotic p
value of 0.000 (Table 5), while the one-tailed test which was performed in Minitab 
yielded a p value of significant p value of 0.000 assuming a confidence level of 95%
(Table 6).
 
n (n +1) U =n n + 1   1  - Sum of Ranks
1 1  2 2
 
U =n n - (U ) 
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Table 4. Mean ranks of Type I and Type II TM protein Shannon entropies
 
 
Table 5. Asymptotic two-tailed p value of Mann-Whitney U test of Shannon entropies
 
Mann-Whitney Test and CI: T1 SE, T2 Hydro
 N Median
T1 Shannon Entropies 1118 2.5708
T2 Shannon Entropies 155 2.7200
Point estimate for 1 - 2 is -0.1438
 
95.0 Percent CI for 1 - 2 is (-0.1970, -0.0889) 
W = 690642.5
Test of 1 = 2 vs 1 < 2 is significant at 0.0000
 








Z Test of Shannon Entropies
 
The results of the two independent sample Z test on the mean Shannon entropies
of Type I and Type II proteins yielded a standard deviation of 4289.2 and a Z-test statistic 
of -5.018, which corresponds to a p value of 0.0000, given n1=1118, n2=155, a =
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Shannon Entropy as a Function of Hydrophobic Energy
 
Shannon entropies of Type I proteins were plotted against hydrophobic energies 
of Type I proteins, and an R2 of 0.221 was obtained (Figure 6). The residual sum of 
squares was computed to be 67.7 (Table 7). Shannon entropies of Type II proteins were 
plotted against hydrophobic energies of Type II proteins, and R2 of 0.232 was obtained 










Table 7. ANOVA table of linear regression analysis of Type I Shannon entropies plotted 




Figure 7. Linear regression analysis of Type II Shannon entropies as a function of Type II 
TM protein hydrophobic energies
 
 
Table 8. ANOVA table of linear regression analysis of Type II Shannon entropies plotted 





The relative abundances of Type I (striped) and Type II (dotted) proteins 
categorized by biological, molecular, and enzymatic function. Among Type I proteins (n
= 1118), those that functioned in immune pathways were the most abundant, followed
closely by those that functioned exclusively as receptors (Figure 8). Similarly, among
Type II TM proteins (n = 155), those that functioned in immune pathways were the most 
abundant, followed by enzymes (Figure 8).
 














The overall Gibb’s free energy difference between Type I and Type II proteins 
was calculated to be approximately 9.63 kJ/mol. The mean hydrophobic energy yielded
by descriptive statistics was calculated to be 231.6 kJ/mol for Type I proteins and 217.1 
kJ/mol for Type II proteins. The difference in the mean hydrophobic energies between
the two types of proteins was calculated to be 14.5 kJ/mol. Thus, the difference in 
hydrophobic energies appears to exceed the free energy difference between Type I and
Type II proteins. Although hydrophobic energy appears to overcompensate for the 
energy disparity between Type I and Type II proteins, this observation may also be 
attributed to energy interactions among a variety of energetic contributors, but more 
research is needed in order to elucidate such factors and their specific roles in energy
compensation.
Z Test of Transmembrane Domain Hydrophobic Energies
 
The results of both the Z test and the Mann-Whitney U test of hydrophobic 
energies indicate that the mean hydrophobic energies of Type I proteins are significantly
greater than the mean hydrophobic energies of Type II proteins (p = 0.0003). The Z-test 
statistic for the hydrophobic energies was |-3.4510| > 1.96 = 0.05, indicating 
rejection of the null hypothesis. The mean rank of Type I protein hydrophobic energies
was calculated to be 650.24, while the mean rank of Type II protein hydrophobic energies
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was calculated to be 541.51. These results indicate significant disparities in the 
hydrophobic energies exhibited by Type I and Type II transmembrane domains.  Given
the estimated differences between the stabilities of Type I and Type II transmembrane 
proteins and the tendency of thermodynamic systems to achieve the lowest energy state 
possible, it may be hypothesized that such differences in hydrophobic energies may have 
arisen due to the energetic disadvantage of Type I protein orientation. The selective 
pressures exerted by energetically unfavorable interactions between the charged dipole
termini and the membrane field potential may impose evolutionary constraints on the 
hydrophobic character of transmembrane domains belonging to bitopic proteins, and 
perhaps those of polytopic proteins. It is possible that increased selection of
transmembrane proteins exhibiting greater hydrophobic character may serve as an
adaptive response to the subsequent energy disadvantages encountered by the globular
termini of Type I proteins. Admittedly, understanding of the mechanisms underlying this
process is still in its infancy, and more research is required to fully elucidate the 
evolutionary link between transmembrane protein selection and the hydropathies of their 
transmembrane domains.
Z Test of Transmembrane Domain Shannon Entropies
 
The results of both the Z test and the Mann-Whitney U test of Shannon entropies 
show that the mean information entropies of Type I transmembrane proteins are 
significantly lower than the Shannon entropies of Type II transmembrane proteins (p =
0.000). The Z-test statistic for Shannon entropies was |-5.018| > 1.96 for = 0.05,
indicating rejection of the null hypothesis. The mean rank of Type I transmembrane 
protein Shannon entropies was calculated to be 617.75, while the mean rank of Type II
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transmembrane protein Shannon entropies was calculated to be 775.86. These results
indicate that the maximum possible states that can be assumed by transmembrane 
domains of Type I proteins are much lower than the maximum possible states that can be 
assumed by Type II proteins. In addition, the amount of information that is needed to 
describe the state of Type I protein transmembrane domains is much lower than that 
needed to describe the state of Type II protein transmembrane domains. These disparities 
may be due to increased hydrophobicity in Type I protein transmembrane domains
relative to their Type II counterparts. This phenomenon may be attributed to the 
biochemical and stereochemical constraints that arise from Type I proteins’ evolutionary
need to assume a lower hydrophobic energy in order to compensate for free energy
disadvantages.  Specifically, the tendency of Type I proteins to exhibit greater
hydrophobicities in order to optimize energetic favorability may require the composition 
of their transmembrane domains to be dominated by hydrophobic residues or site-specific 
burial of hydrophilic side chains.
Linear Regression Analysis of Shannon Entropy as a Function of Hydrophobic Energy
 
The results of the linear regression analysis for Type I proteins reveal a weak
correlation between hydrophobic energy and Shannon entropy (R2 = 0.221, RSS = 67.7).
Similar results were obtained for Type II proteins (R2 = 0.232, RSS = 23.2). The weak
correlation between these two parameters indicates that the information entropies of 
transmembrane domains are not directly proportional to transmembrane domain 
hydrophobic energies. This means that transmembrane domain hydropathies are not the 
sole determinants of transmembrane domain entropies.  Given the results, it may be
hypothesized that overall entropies may actually be a product of multiple interactions
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among several energy inputs. Whether these interactions are additive or synergistic is 




It appears that differences in hydrophobic energy may not directly influence
protein functional roles. This is indicated by the fact that the majority of both Type I and
Type II protein groups were found to function in immune pathways.  For Type I proteins, 
the second most abundant functional role was found to receptors. For Type II proteins, 
the second most abundant functional role was enzymes. It is unclear whether these 
differences may be linked to disparities in hydrophobic energies of transmembrane 
domains.  More research is required to identify any specific correlations between
hydrophobic energy and protein function.
Summary
 
Thermodynamics is the guiding principal that governs all change. Examining the 
thermodynamic mechanisms underlying transmembrane protein stability is critical to
gaining a fundamental understanding of transmembrane protein energetics within lipid 
mediums and the evolutionary mechanisms that regulate their relative populations. This 
study exposes inherent differences between the hydrophobicities and the Shannon 
entropies exhibited by two broad categories of transmembrane proteins. The findings of
this study suggest that transmembrane protein insertion is not a strictly stochastic process
but ultimately one that is selectively governed by biophysical determinants. This study
also reveals that transmembrane domain entropies are not a direct result of hydrophobic
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free energies, but may be attributed to other energetic modulators, although these specific 
agents have yet to be identified.
Many diseases depend upon pathways involving transmembrane proteins and
their functional roles.  Certain diseases may interfere with transmembrane protein
function and disrupt normal pathways, or they may simply use transmembrane proteins to
elicit pathogenicity. Biomedical engineering of appropriate drugs depends very much on
a comprehensive understanding of transmembrane protein stability. By understanding the 
thermodynamic landscape of transmembrane protein stability, researchers can more 
effectively design disease-combatting drugs in order to improve the quality of human
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Activin receptor type-1B 
Activin receptor type-1C 
Activin receptor type-2A 
Activin receptor type-2B
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Anthrax toxin receptor 1
Anthrax toxin receptor 2
Anthrax toxin receptor-like
Antigen-presenting glycoprotein CD1... 
Anti-Muellerian hormone type-2 rece... 
Apical endosomal glycoprotein
Atrial natriuretic peptide receptor...
Atrial natriuretic peptide receptor...
Atrial natriuretic peptide receptor...
Attractin
Attractin-like protein 1
B- and T-lymphocyte attenuator 
Basal cell adhesion molecule 
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B-cell antigen receptor complex-ass... 
B-cell antigen receptor complex-ass... 
B-cell receptor CD22









































































































































Bone morphogenetic protein receptor...
Bone morphogenetic protein receptor...
Bone morphogenetic protein receptor...
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Butyrophilin subfamily 1 member A1
Butyrophilin subfamily 2 member A1
Butyrophilin subfamily 2 member A2
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Cadherin-related family member 2
Cadherin-related family member 3
Cadherin-related family member 4
Cadherin-related family member 5



























































































































































Cation channel sperm-associated pro...
Cation channel sperm-associated pro...
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Cell adhesion molecule 1
Cell adhesion molecule 2
Cell adhesion molecule 3
Cell adhesion molecule 4
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Cell surface glycoprotein CD200 rec... 
Cell surface glycoprotein CD200 rec... 
Cell surface glycoprotein MUC18
Chondroitin sulfate proteoglycan 4
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Coxsackievirus and adenovirus recep...
C-type lectin domain family 14 memb...
C-type mannose receptor 2
CUB and sushi domain-containing pro...
CUB and zona pellucida-like domain-...
CXADR-like membrane protein
C-X-C motif chemokine 16
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Cytokine receptor common subunit be... 
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Cytokine receptor-like factor 2
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Disintegrin and metalloproteinase d...
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Disintegrin and metalloproteinase d...
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Disintegrin and metalloproteinase d...
Disintegrin and metalloproteinase d...
Disintegrin and metalloproteinase d...
Disintegrin and metalloproteinase d...
Disintegrin and metalloproteinase d...
Disintegrin and metalloproteinase d...
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Down syndrome cell adhesion molecul... 
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Dystroglycan
E3 ubiquitin-protein ligase RNF130
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Ephrin type-A receptor 2
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Epidermal growth factor receptor
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Epithelial cell adhesion molecule
Epithelial discoidin domain-contain...
ER membrane protein complex subunit... 
ER membrane protein complex subunit... 
ER membrane protein complex subunit...
Erythroid membrane-associated prote... 
Erythropoietin receptor
E-selectin
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Fc receptor-like protein 1
Fc receptor-like protein 2
Fc receptor-like protein 3
Fc receptor-like protein 4
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Fibroblast growth factor receptor 1
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IGF-like family receptor 1
IgG receptor FcRn large subunit p51
Ig-like V-type domain-containing pr...
Immunoglobulin alpha Fc receptor 
Immunoglobulin superfamily DCC subc...
Immunoglobulin superfamily DCC subc...
Immunoglobulin superfamily member 1...
Immunoglobulin superfamily member 2
Immunoglobulin superfamily member 3
Immunoglobulin superfamily member 5
Immunoglobulin superfamily member 6
Immunoglobulin-like domain-containi... 
Inactive tyrosine-protein kinase 7
Inactive tyrosine-protein kinase tr...
Inducible T-cell costimulator 
Inositol 1,4,5-trisphosphate recept... 
Inositol 1,4,5-trisphosphate recept... 
Insulin receptor
Insulin receptor-related protein Insulin-
like growth factor 1 recept... Integral








































































































































































Intercellular adhesion molecule 1
Intercellular adhesion molecule 2
Intercellular adhesion molecule 3
Intercellular adhesion molecule 4
Intercellular adhesion molecule 5
Interferon alpha/beta receptor 1
Interferon alpha/beta receptor 2
Interferon gamma receptor 1
Interferon gamma receptor 2
Interferon lambda receptor 1
Interleukin-1 receptor accessory pr...
Interleukin-1 receptor accessory pr...
Interleukin-1 receptor type 1
Interleukin-1 receptor type 2
Interleukin-1 receptor-like 1
Interleukin-1 receptor-like 2
Interleukin-10 receptor subunit alp... 
Interleukin-10 receptor subunit bet... 
Interleukin-11 receptor subunit alp... 
Interleukin-12 receptor subunit bet... 
Interleukin-12 receptor subunit bet... 
Interleukin-13 receptor subunit alp... 
Interleukin-13 receptor subunit alp... 
Interleukin-15 receptor subunit alp... 
Interleukin-17 receptor A
Interleukin-17 receptor B 















































































































































Interleukin-17 receptor E 
Interleukin-18 receptor 1
Interleukin-18 receptor accessory p...
Interleukin-2 receptor subunit alph... 
Interleukin-2 receptor subunit beta 
Interleukin-20 receptor subunit alp... 
Interleukin-20 receptor subunit bet... 
Interleukin-21 receptor
Interleukin-22 receptor subunit alp... 
Interleukin-23 receptor
Interleukin-27 receptor subunit alp... 
Interleukin-3 receptor subunit alph... 
Interleukin-31 receptor subunit alp...
Interleukin-4 receptor subunit alph... 
Interleukin-5 receptor subunit alph... 
Interleukin-6 receptor subunit alph... 
Interleukin-6 receptor subunit beta 
Interleukin-7 receptor subunit alph... 
Interleukin-9 receptor 
Interphotoreceptor matrix proteogly...
Izumo sperm-egg fusion protein 1
Izumo sperm-egg fusion protein 2
Izumo sperm-egg fusion protein 3
Junctional adhesion molecule A
Junctional adhesion molecule B 
Junctional adhesion molecule C 
Junctional adhesion molecule-like 
Keratinocyte-associated transmembra...
Killer cell immunoglobulin-like rec...
Killer cell immunoglobulin-like rec...
Killer cell immunoglobulin-like rec...
Killer cell immunoglobulin-like rec...
Killer cell immunoglobulin-like rec...
Killer cell immunoglobulin-like rec...
Killer cell immunoglobulin-like rec...
Killer cell immunoglobulin-like rec...
Killer cell immunoglobulin-like rec...
Killer cell immunoglobulin-like rec...
Killer cell immunoglobulin-like rec...
Killer cell immunoglobulin-like rec...
Killer cell immunoglobulin-like rec...
Killer cell immunoglobulin-like rec...
Killer cell immunoglobulin-like rec...
Kin of IRRE-like protein 1
Kin of IRRE-like protein 2
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Leucine-rich repeat and fibronectin...
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Leucine-rich repeat and immunoglobu... 
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Leucine-rich repeat and immunoglobu... 
Leucine-rich repeat and immunoglobu... 
Leucine-rich repeat and transmembra...
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Leucine-rich repeat neuronal protei... 
Leucine-rich repeat neuronal protei... 
Leucine-rich repeat neuronal protei...
Leucine-rich repeat neuronal protei... 
Leucine-rich repeat transmembrane n...
Leucine-rich repeat transmembrane n...
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Leucine-rich repeat transmembrane n...
Leucine-rich repeat-containing prot... 
Leucine-rich repeat-containing prot... 
Leucine-rich repeat-containing prot... 
Leucine-rich repeat-containing prot... 
Leucine-rich repeat-containing prot... 
Leucine-rich repeat-containing prot... 
Leucine-rich repeat-containing prot... 
Leucine-rich repeat-containing prot... 
Leucine-rich repeat-containing prot... 
Leucine-rich repeat-containing prot... 
Leucine-rich repeats and immunoglob... 
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Low affinity immunoglobulin gamma F...
Low affinity immunoglobulin gamma F...
Low affinity immunoglobulin gamma F...
Low affinity immunoglobulin gamma F...
Low-density lipoprotein receptor
Low-density lipoprotein receptor cl... 













Lymphatic vessel endothelial hyalur...
Lymphocyte activation gene 3 protei... 




Macrophage colony-stimulating facto... 
Macrophage mannose receptor 1
Macrophage-expressed gene 1 protein 
Macrophage-stimulating protein rece...
Macrosialin
Major histocompatibility complex cl... 
MANSC domain-containing protein 1
MANSC domain-containing protein 4




















































































































































Membrane protein FAM174A 
Membrane protein FAM174B 
Meprin A subunit alpha 




MHC class I polypeptide-related seq...
MHC class I polypeptide-related seq...
Microfibril-associated glycoprotein... 







Mucosal addressin cell adhesion mol... 
Multiple epidermal growth factor-li...
Multiple epidermal growth factor-li...
Multiple epidermal growth factor-li...
Multiple epidermal growth factor-li...
Muscle, skeletal receptor tyrosine-...
Myelin protein P0
Myelin protein zero-like protein 1
Myelin protein zero-like protein 2
Myelin protein zero-like protein 3
Myelin-associated glycoprotein
Myeloid cell surface antigen CD33
Natural cytotoxicity triggering rec...
Natural cytotoxicity triggering rec...
Natural cytotoxicity triggering rec...
Natural cytotoxicity triggering rec...
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Neurogenic locus notch homolog prot... 
Neurogenic locus notch homolog prot... 






Neuronal cell adhesion molecule 
Neuropilin and tolloid-like protein... 









Noncompact myelin-associated protei... 
NT-3 growth factor receptor
Oncostatin-M-specific receptor subu... 
Opalin
OX-2 membrane glycoprotein
Paired immunoglobulin-like type 2 r...




Phospholipase B1, membrane-associat... 
PILR alpha-associated neural protei... 
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Platelet glycoprotein Ib alpha chai... 
Platelet glycoprotein Ib beta chain
Platelet glycoprotein IX
Platelet glycoprotein V
Platelet-derived growth factor rece...
Platelet-derived growth factor rece...
Plexin domain-containing protein 1
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Programmed cell death 1 ligand 2
Programmed cell death protein 1
Proheparin-binding EGF-like growth ... 
Prolactin receptor
Proline-rich membrane anchor 1
Prolow-density lipoprotein receptor...
Pro-neuregulin-1, membrane-bound is... 
Pro-neuregulin-2, membrane-bound is... 
Pro-neuregulin-3, membrane-bound is... 
Pro-neuregulin-4, membrane-bound is... 
Proprotein convertase subtilisin/ke...
Proprotein convertase subtilisin/ke...
Prostaglandin F2 receptor negative ...
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Protransforming growth factor alpha
P-selectin
P-selectin glycoprotein ligand 1
Putative butyrophilin subfamily 2 m... 
Putative FXYD domain-containing ion... 
Putative protein shisa-8
Putative T-cell surface glycoprotei... 
Putative uncharacterized protein C1...
Putative uncharacterized protein FL...
Receptor activity-modifying protein... 
Receptor activity-modifying protein... 
Receptor activity-modifying protein... 
Receptor tyrosine-protein kinase er...
Receptor tyrosine-protein kinase er...
Receptor tyrosine-protein kinase er...
Receptor-type tyrosine-protein kina...
Receptor-type tyrosine-protein phos... 
Receptor-type tyrosine-protein phos... 
Receptor-type tyrosine-protein phos... 
Receptor-type tyrosine-protein phos... 
Receptor-type tyrosine-protein phos... 
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Retinal guanylyl cyclase 1
Retinal guanylyl cyclase 2
Retinoic acid early transcript 1G p... 




Scavenger receptor class F member 1
Scavenger receptor class F member 2
Scavenger receptor cysteine-rich ty...
Scavenger receptor cysteine-rich ty...
Secreted and transmembrane protein ... 
Secretory phospholipase A2 receptor 
Seizure 6-like protein
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Signal-regulatory protein beta-1 is... 
Signal-regulatory protein beta-2
Signal-regulatory protein gamma
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SLAM family member 6
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SLAM family member 8
SLAM family member 9
SLIT and NTRK-like protein 1
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SLIT and NTRK-like protein 4
SLIT and NTRK-like protein 5
SLIT and NTRK-like protein 6
Small integral membrane protein 7
Small integral membrane protein 9
Sodium channel subunit beta-1
Sodium channel subunit beta-2
Sodium channel subunit beta-3
Sodium channel subunit beta-4
Sortilin
Sortilin-related receptor
Sperm acrosome membrane-associated ... 
Sperm acrosome membrane-associated ... 
Stabilin-1
Stabilin-2
Stromal interaction molecule 1
Stromal interaction molecule 2
Sushi domain-containing protein 1
Sushi domain-containing protein 2
Sushi domain-containing protein 4
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T-cell surface antigen CD2
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T-cell surface glycoprotein CD3 del... 
T-cell surface glycoprotein CD3 eps... 
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T-cell surface glycoprotein CD3 zet...
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T-cell surface protein tactile
T-cell-interacting, activating rece...











Thrombospondin type-1 domain-contai... 
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Tissue factor
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T-lymphocyte activation antigen CD8... 
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Transforming growth factor beta rec...
Trans-Golgi network integral membra...
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Transmembrane glycoprotein NMB 
Transmembrane inner ear expressed p... 
Transmembrane protein 119
Transmembrane protein 130
Transmembrane protein 131-like 
Transmembrane protein 132A 
Transmembrane protein 132B 
Transmembrane protein 132C 
Transmembrane protein 132D 













Trem-like transcript 1 protein Trem-
like transcript 2 protein Triggering
receptor expressed on my... Triggering
receptor expressed on my...
Trophoblast glycoprotein
Trophoblast glycoprotein-like
Tumor necrosis factor receptor supe... 
Tumor necrosis factor receptor supe... 
Tumor necrosis factor receptor supe... 
Tumor necrosis factor receptor supe... 
Tumor necrosis factor receptor supe... 
Tumor necrosis factor receptor supe... 
Tumor necrosis factor receptor supe... 
Tumor necrosis factor receptor supe... 
Tumor necrosis factor receptor supe... 
Tumor necrosis factor receptor supe... 
Tumor necrosis factor receptor supe... 
Tumor necrosis factor receptor supe...














































































































































Tumor necrosis factor receptor supe...
Tumor necrosis factor receptor supe...
Tumor necrosis factor receptor supe...
Tumor necrosis factor receptor supe...
Tumor necrosis factor receptor supe...
Tumor necrosis factor receptor supe...
Tumor necrosis factor receptor supe...
Tumor necrosis factor receptor supe...
Tumor protein p53-inducible protein... 
Tumor-associated calcium signal tra...
TYRO protein tyrosine kinase-bindin...
Tyrosine-protein kinase Mer
Tyrosine-protein kinase receptor Ti...
Tyrosine-protein kinase receptor TY... 
Tyrosine-protein kinase receptor UF...
Tyrosine-protein kinase RYK
Tyrosine-protein kinase transmembra...


















Vascular cell adhesion protein 1
Vascular endothelial growth factor ... 
Vascular endothelial growth factor ... 
Vascular endothelial growth factor ... 
Vasorin
Very low-density lipoprotein recept... 
Vesicular, overexpressed in cancer,...
Voltage-dependent calcium channel s... 
Voltage-dependent calcium channel s... 
Voltage-dependent calcium channel s... 



















































































































V-set and immunoglobulin domain-con... 
V-set and immunoglobulin domain-con...
V-set and immunoglobulin domain-con... 
V-set and immunoglobulin domain-con... 
V-set and immunoglobulin domain-con... 
V-set and immunoglobulin domain-con... 
V-set and transmembrane domain-cont... 
V-set and transmembrane domain-cont... 
V-set and transmembrane domain-cont... 
V-set domain-containing T-cell acti...
V-type immunoglobulin domain-contai... 
VWFA and cache domain-containing pr...
X-linked interleukin-1 receptor acc...
Zona pellucida sperm-binding protei... 
Zona pellucida sperm-binding protei... 
Zona pellucida sperm-binding protei... 
Zona pellucida sperm-binding protei... 
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4F2 cell-surface antigen heavy chai... 
Adipocyte plasma membrane-associate... 




Atrial natriuretic peptide-converti... 




Bombesin receptor-activated protein... 






Collagen alpha-1(XIII) chain 
Collagen alpha-1(XVII) chain 
Collagen alpha-1(XXIII) chain 
Collagen alpha-1(XXV) chain 
Collectin-12
C-type lectin domain family 1 membe... 
C-type lectin domain family 1 membe... 
C-type lectin domain family 10 memb... 
C-type lectin domain family 12 memb... 
C-type lectin domain family 12 memb... 
C-type lectin domain family 17, mem... 
C-type lectin domain family 2 membe... 
C-type lectin domain family 2 membe... 
C-type lectin domain family 2 membe... 
C-type lectin domain family 4 membe... 
C-type lectin domain family 4 membe... 
C-type lectin domain family 4 membe... 
C-type lectin domain family 4 membe... 
C-type lectin domain family 4 membe... 
C-type lectin domain family 4 membe... 
C-type lectin domain family 4 membe... 
C-type lectin domain family 4 membe... 




































































































































C-type lectin domain family 6 membe... 
C-type lectin domain family 7 membe...
C-type lectin domain family 9 membe... 
C-type lectin-like domain family 1
Cytoskeleton-associated protein 4
Delta-sarcoglycan
Dipeptidyl aminopeptidase-like prot... 
Dipeptidyl peptidase 4
Dysferlin















HLA class II histocompatibility ant... 
Inactive dipeptidyl peptidase 10
Inactive N-acetylated-alpha-linked ... 
Interferon-induced transmembrane pr...
Kell blood group glycoprotein
Killer cell lectin-like receptor su... 
Killer cell lectin-like receptor su... 
Killer cell lectin-like receptor su... 
Killer cell lectin-like receptor su... 
Kita-kyushu lung cancer antigen 1
Leucyl-cystinyl aminopeptidase
Low affinity immunoglobulin epsilon...
Lymphotoxin-beta
Macrophage receptor MARCO
Macrophage scavenger receptor types... 
Mast cell-expressed membrane protei... 
Membrane frizzled-related protein 


















































































































































N-acetylated-alpha-linked acidic di... 
Natural killer cells antigen CD94
Neprilysin
Neuronal pentraxin receptor
Neutral and basic amino acid transp... 
NKG2-A/NKG2-B type II integral memb... 
NKG2-C type II integral membrane pr...
NKG2-D type II integral membrane pr...
NKG2-E type II integral membrane pr...
NKG2-F type II integral membrane pr...
Otoferlin






Plasmalemma vesicle-associated prot... 





Putative signal peptidase complex c...
Radiation-inducible immediate-early...
Scavenger receptor class A member 3
Scavenger receptor class A member 5
Serine protease hepsin




Sperm acrosome membrane-associated ... 





Transferrin receptor protein 1
Transferrin receptor protein 2
Transmembrane protease serine 11A 
Transmembrane protease serine 11B
Transmembrane protease serine 11D 
Transmembrane protease serine 11E 
Transmembrane protease serine 11F






















































































































Transmembrane protease serine 2
Transmembrane protease serine 3
Transmembrane protease serine 4
Transmembrane protease serine 5
Transmembrane protease serine 6
Transmembrane protease serine 7
Transmembrane protease serine 9
Transmembrane protein 5
Tumor necrosis factor
Tumor necrosis factor ligand superf...
Tumor necrosis factor ligand superf...
Tumor necrosis factor ligand superf...
Tumor necrosis factor ligand superf...
Tumor necrosis factor ligand superf...
Tumor necrosis factor ligand superf...
Tumor necrosis factor ligand superf...
Tumor necrosis factor ligand superf...
Tumor necrosis factor ligand superf...
Tumor necrosis factor ligand superf...
Tumor necrosis factor ligand superf...
Uncharacterized family 31 glucosida...
Zeta-sarcoglycan
186.19
254.39
266.94
178.66
227.61
242.67
212.97
141.84
182.84
195.81
195.39
224.68
199.58
170.29
187.44
227.19
228.86
253.55
225.10
240.16
206.27
227.19
2.623
2.207
2.242
2.296
2.486
2.665
2.720
3.082
3.154
3.078
2.910
1.991
2.642
2.506
2.528
2.739
3.180
2.554
2.901
2.200
2.599
2.915
 
